Upload
michael-adeniya
View
85
Download
0
Embed Size (px)
Citation preview
1 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
First draft agenda
DAY 1
Wednesday, September 21st 2016
7.25 Registration & buffet breakfast in the exhibition area
Opening plenary session
Driving increased pharma and VC investment in European
immunotherapy
8.45 Chair’s introduction
Setting the scene: Analysing key successes and failures for European immunotherapy in
2015/16
What have been the key deals and collaborations in Europe over the past 12 months?
Where can we expect the biggest breakthrough stories to come from in immuno-
oncology?
Dr Sam Fazeli, Senior Pharmaceutical Analyst & European Head, Bloomberg Intelligence
9.10 Presentation reserved
9.30 European and US VCs and analysts on the keys to winning the battle for investment in
cancer immunotherapy
Presentations & Panel
Analysing recent European investment trends in the immunotherapy space
o Are current VC investment levels in Europe an indicator that immunotherapy is
finally set to disrupt cancer healthcare on the continent?
Financing insights for Europe’s immunotherapy biotech community: how to successfully
engage VCs from the US, Europe and further afield?
o What specific data do they need to see from the industry in order to invest?
o How to de-risk your business model and R&D portfolio to gain investors’
confidence?
o How can the US investment community stimulate innovation in the European
research environment? Is there a fertile ecosystem for US investors to enter
Europe? Are there any challenges to stop them investing here?
2 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
Forecasting developments to the European and global IPO environments for
immunotherapy companies over the short- to mid-terms
Dr Vincent Brichard, Venture Partner, (LSP) Life Sciences Partners
Dr Kristina Kakalacheva, Associate, Nextech Invest Ltd
Dr Joshua Resnick, Partner, SV Life Sciences
Giovanni Mariggi, Principal, Medicxi Ventures
10.15 Big Pharma collaborative strategies in immuno-oncology: How can Europe’s biotech
and academic communities capitalise?
Keynote Presentations & Panel
Analysing recent deals between Big Pharma and biotech – what learning can be taken
away?
o Is the immuno-oncology deal frenzy calming down or is this just the beginning?
o Acquisition strategies: What are they looking for in small to mid-sized biotechs?
How are they looking to work with academia?
How are Big Pharma R&D portfolios set to evolve and where do their specific interests lie
in terms of immunotherapy technology areas and indications?
Panellists:
Dr Roy Baynes, SVP, Global Clinical Development, Merck Sharpe & Dohme
Donnie McGrath, Vice President, Head Search & Evaluation, Business Development,
Bristol-Myers Squibb
Dr. Michael S. Perry, Chief Scientific Officer, Global Business Development & Licensing
(BD&L), Novartis
Niels Emmerich, Senior Director, Global Head Search & Evaluation Oncology, Abbvie,
Inc
11.05 Close of session – morning coffee in the exhibition area
Then
Plenary
Preparing for adoption of novel European pricing and reimbursement
models by the evolving oncology healthcare marketplace
11.45 Chairs introduction
11.50 Payer’s priorities for immunotherapy
Assessment, pricing and reimbursement for immuno-oncology drugs
Are present payment models appropriate or do we need alternatives?
Dr Detlev Parow, Head of Department, Care Management Development, DAK-Gesundheit
3 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
12.00 Health Technology Assessment (HTA) and payer views; predicting the future for
immuno-oncology pricing and reimbursement strategies
How will Europe’s HTAs use value-based assessment to decide which drugs should be
brought into society?
o How can value be assessed effectively and efficiently for potentially curative
immunotherapies?
What methodological approaches are being used by European
HTA’s?
Is QALY the appropriate method to use for assessment of these
technologies?
Driving an increased uptake of breakthrough immunotherapies in Europe: how can we
streamline market access across the continent?
o How are HTA and payer bodies planning to create a framework for centralised
decision making?
o How can the industry streamline commercialisation plans across Europe as a whole
considering the differences of P&R policies at a national level?
Analysing cost control opportunities along the length of the development cycle: Where can
efficiencies be achieved?
Assessing the requirement for biomarkers: will they help in justifying the high price tag of
immunotherapies?
o What role will companion diagnostics play in reimbursement of immuno-oncology
agents moving forward?
How will CART and other personalised medicines be evaluated? What reimbursement model
might work for a Euro300,000-a-dose drug?
o What does rational pricing for these products look like?
Identifying a viable reimbursement plan and pricing structure for combination therapies
o Will Europe’s payers view them as two separate drugs and therefore two separately
priced elements?
What factors play a key role in the approval of a combination immunotherapy from a
reimbursement point of view?
o Are side effects taken into account in cost-value calculations or is it all about
efficacy?
Dr Nick Crabb, Programme Director, Scientific Affairs, National Institute for Health &
Clinical Excellence (NICE) – UK
Dr Detlev Parow, Head of Department, Care Management Development, DAK-Gesundheit
Dr César Hernández-Garcia, Head of Department, Department of Medicines for Human
Use, Spanish Medicine Agency (AEMPS) – Spain
Dr Marc Matar, Partner, Simon-Kucher & Partners
4 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
1.25 Buffet lunch in the exhibition area
Followed by your choice of 3 highly interactive
parallel breakout streams:
Stream 1 (Shared with the Cell & Gene Therapy stream)
Piecing together the strategic manufacturing jigsaw to deliver lasting
commercial viability and success: part 1
2.25 Chair’s introduction
Dr Anthony Davies, President, Dark Horse Consulting
‘Case study’ perspectives from leading ex vivo gene therapy and cell therapy developers in late-
stage clinical development, covering both large and orphan indications - how are autologous
and allogeneic manufacturing business models for both scale-up and scale-out taking shape in
Europe as technical innovation and the manufacturing services sector continue to evolve?
Dissecting decision-making processes around fundamental questions for commercial supply:
outsource or manufacture in-house? (And if you outsource, when to do so? Examining the pros
and cons of making the outsourcing decision at Phase I/II, pivotal and commercial scales)
How will the supply chain be managed? What does the infrastructure look like?
What are the key regulatory obstacles to consider in terms of designing and validating the
bioprocess and supply chain?
Can we quantify the impact on the costs of development/goods if you need to make changes – for
example, to a formulation in late Phase II or Phase III clinical trials?
2.30 Presentation
Dr Stefan Wildt, Vice President, Global Head Technical Research & Development, Cell &
Gene Therapies, Novartis
2.50 Presentation reserved
3.10 Addressing massive and complex datasets generated by manufacturing of autologous
cell therapy products
Gathering information and performing massive data analysis and statistics throughout an
autologous process: how to be exhaustive and relevant?
Rationalisation of the information and identification of potential root causes
Raising up conclusions based on the analysis results
Dr Arnaud Lacombe, Project Manager, MaSTherCell
12.30 Phacilitate lab session: Addressing the real life challenge of market access for immuno-
oncology drugs
This session is designed for those who want to collaborate ideas with their peers on market access in
order to deliver actionable objectives. Take the opportunity to learn from those who share your
problems and enjoy mapping out new opportunities. Would you or your organisation like to lead this
unique session? Contact Michael Adeniya now on [email protected] or on +44
(0)2073847951
5 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
3.30 Harnessing the state-of-the-art in closed automated systems and disposables to maximise
efficiency and minimise Cost of Goods
Presentations, followed by panel discussion
How to combine the core biology of bioprocess with cutting edge engineering and
devices to deliver the most cost effective, regulatory-efficient/effective manufacturing
solution?
How are standardisation initiatives advancing and with what impact in real terms?
Dr Ohad Karnieli, Founder & CTO, Karnieli Ltd; Chair, Process & Product Development
Committee, ISCT
Dr Lothar Germeroth, Senior Vice President & Managing Director, Juno Therapeutics
GmbH
4.05 Afternoon tea in the exhibition area
Or
Stream 2 (Shared with the Cell & Gene Therapy stream)
Preclinical-clinical translation: minimising timeframes, maximising insight
2.25 Chair’s introduction
2.30 Case study
Title to be announced
Jean-Philippe Combal, Chief Operating Officer, GenSight Biologics
2.45 Presentation reserved
Case studies: Innovative designs for exploratory studies in humans
3.00 Case study 1
Dr Luise Weigand, Team leader, Cell Biology/ Research Management, Immunocore Ltd
3.15 Case study 2
Denis Dufrane (MD, MsC,PhD), Chief Scientific Officer & Co-Founder, Novadip
Biosciences
3.30 Panel: What makes an optimal animal model for immunotherapy development from
European academic, industry and regulators’ perspectives?
Reflections on the relevance and acceptability to European regulators of animal model
data in support both of clinical trial applications and of product characterization and
potency data – which models are industry and academic developers using most
frequently? Which are the most clinically relevant? What are the regulators’ preferences
in this regard? What are the key new models to consider? Speakers of the session plus
Dr Christopher Bravery, Director, Advanced Biologicals Ltd
6 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
4.05 Afternoon tea in the exhibition area
Or
Stream 3
Boosting success rates in immuno-oncology clinical trials through
biomarker-driven patient selection
2.25 Chair’s introduction
2.30 Presentation: How are big pharma implementing biomarkers in their cancer
immunotherapy clinical strategy?
Dr Jeff Evelhoch, Vice President, Translational Biomarkers, Merck, Sharp & Dohme
2.50 Questions & discussion
2.55 Presentation: Imaging Biomarkers- the application of advanced image processing and
analysis to clinical decision making
Reserved
3.15 Questions & discussion
3.20 Panel: Assessing how biomarkers can be used for predicting clinical benefit and adverse
events in cancer immunotherapy
Examining biomarker-driven methods for improving the activity of immunotherapies in
patients
o Can predictive biomarkers be used as a reliable tool to identify responders?
o What can we learn from biomarkers that are already on the market for predicting
outcomes with checkpoint inhibitor antibodies?
o Understanding why certain patients respond: can these patients reveal valuable
biomarkers?
o With those patients unlikely to respond, are there any biological clues to suggest
other clinical pathways?
What role will the understanding of signal pathways play in recognizing the appropriate
patient population to determine the efficacy and safety profile of these immunotherapies?
Tumour resistance: how do we address the redundant pathways that can contribute to the
suppression of an effective immune response?
Which type of biomarker has the most potential for clinical utility?
Speakers of the session plus:
Dr Paul Robbins, Senior Director, Translational Development, Pfizer, Inc
Dr Thomas Hoeger, Chief Executive Officer, Apogenix AG
4.05 Afternoon tea in the exhibition area
7 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
Followed by your choice of 3 highly interactive
parallel breakout streams:
Stream 1 (Shared with the Cell & Gene Therapy stream)
Piecing together the strategic manufacturing jigsaw to deliver lasting
commercial viability and success: part 2
4.45 Maximizing allogeneic cell therapy starting material through strict donor criteria,
selection, management, and repeat collections
A presentation focused on efficient and effective leukapheresis collection within an FDA-
registered cGMP donor facility for starting material procurement for allogeneic cell
therapies
Discuss why strict donor criteria, selection, management, and repeat collections are
critical for maximizing allogeneic cell therapy production.
Review what increases the chances for high quality starting material: apheresis expertise;
quality of leukapheresis collection; donor center that meets FDA cGMP/cGTP
requirements; process control using stringent SOPs, etc.
Louis Juliano, Senior Vice President, Global Sales & Business Development, HemaCare
Corporation
4.55 Strategies for securing the required capacity for ATMP manufacture at each stage of
development – from preclinical-clinical translation through to commercial scale
Presentations & panel discussion
Pharma/biotech strategic insights: optimising collaborative strategies with CMOs and
other critical stakeholders
Creative approaches to overcoming Europe’s GMP capacity shortfall: how diverse public
and private sector organizations are employing innovative partnering models and
initiatives to meet ATMP manufacturing needs at commercial scale
Speakers/panellists:
Professor Dr Martin Hildebrandt, Director of Manufacturing Facility, Qualified Person,
Technischen Universität München (TUM)
Ajan Reginald, Chief Executive Officer, Cell Therapy Limited
Louis Juliano, Senior Vice President, Global Sales & Business Development, HemaCare
Corporation
Dr Nina Kotsopoulou, Director, Process Development, Autolus
Ulrike Verzetnitsch, Chief Technical Officer, apceth GmbH & Co. KG
5.45 Closing panel: Presenting a vision for the future industrialization of ATMPs in Europe
A panel of enablers covering every stage of the commercial ATMP supply chain – from raw
materials through bioprocessing and product release to logistics and delivery to the patient –
will answer the industry’s key questions on how to deal with remaining obstacles, and how
ongoing collaborative and standardization efforts can help deliver viable end-to-end
solutions for industry
6.25 Close of day 1, followed by a drinks reception
8 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
Or
Stream 2
Next generation approaches to Immuno-Oncology: what will the next wave
of investigative therapies, tools and technologies deliver?
How will they overcome the challenge of significantly increasing
efficacy?
Will they unlock novel cancer targets?
4.45 Chairs introduction
4.50 Presentation: The revival of the bispecific antibody field; what do these novel bispecifics
promise to deliver?
Dr Lex Bakker, SVP & Chief Development Officer, Merus
5.10 Questions & discussion
5.15 Presentation reserved
5.35 Questions & discussion
5.40 Presentation
Dr AnnChristine Thastrom, Clinical Scientist, PDO Clinical Development, Genentech, Inc
6.00 Questions & discussion
6.05 Further questions for the speakers and panel discussion
6.25 Close of day 1, followed by a drinks reception
DAY 2
Thursday, September 22nd
2016
7.25 Registration & buffet breakfast in the exhibition area
Opening plenary session
Establishing a commercially viable immuno-oncology combination therapy
model
Success stories and learnings from the most exciting novel targets and technologies in the
European immunotherapy field: where will the next commercial breakthrough come from?
9 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
8.45 Chair’s introduction
8.50 Opening keynote
Donnie McGrath, Vice President, Head Search & Evaluation, Business Development,
Bristol-Myers Squibb
9.05 Questions & discussion
9.10 Presentation reserved
9.30 Analysing the commercial partnering model in industry and academia for the future
development of immuno-oncology combination therapies
Presentations & Panel
Presentation (5-10 minutes): Dr Hazel Jones
What criteria are big pharma using to choose their different cancer immunotherapy
combinations across the industry?
o Are there any issues with the data that early stage biotechs are showing to the
established checkpoint inhibitor pharma companies?
o Are there any learnings that can be taken from the combination partnering model
BMS works with?
Overcoming the commercial challenges for industry/academia working together and
sharing data
Bringing together specialists from two separate modalities: can we define best practice for
this form of collaboration?
Are both companies involved in the trial sharing the clinical operations management
responsibilities?
How are companies approaching cost management? Are the costs divided equally
between the organisations involved or are there other models they are working to?
Panellists
Donnie McGrath, Vice President, Head Search & Evaluation, Business Development,
Bristol-Myers Squibb
Dr Hazel Jones, Head of Combination Therapies, Cancer Research UK
Steven King, President & CEO, Peregrine
Frederic Ors, CEO, Immunovaccine
10.20 Close of session
Then
10.25-11.25
Interactive hour
10 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
A choice of several highly interactive sessions in varying formats, including small
roundtables, workshops, technology briefings and biotech showcases
11.25 Morning coffee in the exhibition area
Followed by your choice of 2 highly interactive
parallel breakout streams:
Stream 1
Checkpoint inhibitor-based combination therapies- is clinical data
justifying the hype?
12.05 Chair’s introduction
12.05 Chairs Introduction
12.10 Case study 1- Title to be announced
Dr Andrea Van Elsas, Chief Scientific Officer, Aduro Biotech Europe
12.25 Questions & Discussion
12.30 Case study 2- Reserved
12.45 Questions & Discussion
12.50 Closing Panel: How will checkpoint combination therapies work in the clinic and
beyond?
Physician perspective: How are we going to make these combinations work in practical
application at the coalface of cancer healthcare?
Analysing optimal approaches with checkpoint inhibitor combination studies
o Is it best to dose sequentially or simultaneously, or should this be decided on a
case-by-case basis?
How are biomarkers being used to rationally design checkpoint inhibitor
combination therapies?
How should a decision be made on the timing between doses?
o Can the immune system be made intelligent enough to correct the pathway in
response to various on-off signals that try to push the cascade off course?
What can be learned from checkpoint inhibitor combinations already in the clinic? Are
there any key challenges that need to be addressed?
What is at the forefront of innovation in combination therapy clinical trial design?
Case studies: How is the latest data from checkpoint inhibitor-based combination studies
shaping the industry’s ongoing R&D and commercial strategies?
11 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
o What trial designs are proving optimal for the efficient evaluation of novel
combinations?
Without accurate preclinical models what data should be shown to bring the checkpoint
inhibitor combination study into phase 1?
Which checkpoint combinations are showing the best complementary mechanisms of
action?
Reconfiguring drug development to respond to the needs of a very specific marketplace:
The potential and challenges of Dual-Novel immuno-oncology combinations
o How do we conduct first-in-man novel-novel combination studies?
o What is being done to lower the safety and high risk profiles for these
combinations?
o How to overcome regulatory pathway uncertainty to drive these studies?
Panellists
Dr Andrea Van Elsas, Chief Scientific Officer, Aduro Biotech Europe
Dr Tony De Fougerolles, Chief Scientific Officer, Ablynx
Prof Martin Schuler, Director, Cancer Centre, University Hospital Essen
1.25 Buffet lunch in the exhibition area
Or
Stream 2 (Shared with the Cell & Gene Therapy stream)
How are the world’s modified T cell immunotherapy leaders gearing up for
market in Europe?
Can we take the best from both autologous and allogeneic approaches to
inform next-generation development?
12.05 Chair’s introduction
12.10 Dissecting the latest clinical data and commercial business models for leading European
and US CAR T cell and TCR therapy developers
Presentations & panel discussion
How is the latest clinical data shaping future trial designs and development pathways?
How are regulatory differences between North America and Europe impacting
approaches on each continent?
o Planning to meet European national regulatory requirements beyond
centralised market approval in Europe (eg. GMO requirements)
What’s the latest progress in alleviating safety concerns?
Examining autologous vs allogeneic approaches: how far advanced is commercial supply
chain development for each? What are the signs that allogeneic approaches can deliver
the same game-changing efficacy? Is there room for both in the marketplace of the
future?
Progress with and priorities for next-generation approaches: how to remain nimble in
your R&D portfolio management/resourcing and supply chain development in such a fast
moving technology area?
Panellists
12 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
Andre Choulika, Chairman & CEO, Cellectis
Dr Cedrik Britten, Head Cellular Therapy, Immuno-Oncology, GlaxoSmithKline
James Noble, CEO, Adaptimmune
Shawn Tomasello, Chief Commercial Officer, Kite Pharma
Dr Lothar Germeroth, Senior Vice President & Managing Director, Juno
Therapeutics GmbH
12.55 …and multiple stakeholder panel discussion:
What potential pricing & reimbursement model(s) do we envisage for these products in
Europe?
Market exclusivity and CD19: how to differentiate beyond first-to-market?
Beyond conditional approval, what sort of efficacy data will be needed for modified T
cell therapies?
o Will a randomized clinical trial to demonstrate comparative effectiveness
with the Standard of Care be a requirement? Is there a realistic approach to
doing comparative head-to-head studies with existing products?
Speakers of the session plus:
Dr Maria Cristina Galli, Chair of the ATMP Platform, EATRIS-ERIC, the European
Infrastructure for Translational Medicine; Department of Cell Biology & Neurosciences,
Istituto Superiore di Sanità, Italy
1.25 Buffet lunch in the exhibition area
Then
Plenary (Shared with the Cell & Gene Therapy stream)
Assessing the prospects of next-generation cellular immunotherapies
entering the clinic – how will they improve upon the first wave?
CAR 2.0
Second generation TCRs
NK cells
2.25 Chair’s introduction
2.30 What improvements can second and third generation CAR- and TCR-based
immunotherapies offer in terms of both safety and persistence of response?
Presentations & panel discussion
How to improve the safety profile of these technologies?
o Harnessing suicide genes
o Utilising selective memory T cells to control toxicity
What do we now know in terms of which T cells to use for longer lasting effects?
Dr Richard Morgan, VP Immunotherapy, bluebird bio
Dr Kai Pinkernell, Chief Medical Officer, Medigene
3.00 What is the future for NK Cells?
Presentations & panel discussion
13 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
How do they shape up against T cell approaches in terms of safety and efficacy - what are
their pros and cons in comparison?
Will autologous or allogeneic NK cell therapies win the day?
What role will combination approaches play in developing the NK Cell therapy field?
How to overcome fundamental challenges in NK cell therapy development?
o Obtaining sufficient numbers of expanded/corrected NK cells
o How to transfect NK cells efficiently?
o How to ensure they are functional?
o How to enhance cell survival in vivo without increasing risk of toxicity?
Dr Hans Klingemann, Vice President, R&D, NantKwest, Inc
Dr Torsten Tonn, CEO, German Red Cross Blood Donation Service North-East;
Professor Transfusion Medicine, Dresden University of Technology
Dr. Winfried Wels, Professor for Tumor Biology and Deputy Director, Georg-Speyer-
Haus, Institute for Tumor Biology and Experimental Therapy Frankfurt, Germany
Dr Jens-Peter Marschner, CMO, Affimed
3.40 Closing panel discussion
How are gene editing platforms being applied to improve next generation T cell and NK
cell immunotherapies?
o What does the early data suggest in terms of how it will affect safety and
efficacy in clinical application?
Beyond cancer – what impact can T cell and NK cell immunotherapies have on the
antiviral and autoimmune areas?
Panellists
Dr Hans Klingemann, Vice President, R&D, NantKwest, Inc
Dr Miguel Forte, Chief Operating Officer, TxCell SA
Dr Richard Morgan, VP Immunotherapy, bluebird bio
Dr Vincent Brichard, Venture Partner, (LSP) Life Sciences Partners
4.05 Afternoon tea in the exhibition area
Plenary (Shared with the Cell & Gene Therapy stream)
Targeting solid tumours: how to enable the next great step in cellular
cancer immunotherapy?
4.25 Chair’s introduction
Linda Powers, CEO, Northwest Biotherapeutics
4.30 Beyond CD19: what progress to date in the search for targets that can unlock solid
tumours for CART, TCRs and other cellular immunotherapies?
Case studies & panel discussion
Comparative analysis of existing data for CAR T cell and TCR immunotherapies against
solid tumours – which shows the greatest promise to date?
Can we find good targets in solid tumours that lend themselves to CAR- and TCR-based
immunotherapy and avoid the threat of B cell depletion?
14 Phacilitate Immunotherapy Europe 2016, 21st – 22
nd September, Maritim Proarte, Berlin.
Draft Agenda – Strictly Private & Confidential © Clarion Events 2016 For more information, please contact Kim Evans on 02073847993
Panellist:
Peter Hoang, SVP, Business Development & Strategy, Bellicum
Dr Madhusudan Peshwa, Chief Scientific Officer, Maxcyte
Dr Helen Tayton-Martin, COO, Adaptimmune
5.05 Presentation
Dr Werner Lubitz, Chief Executive Officer & Chief Scientific Officer, BIRD-C GmbH
5.25 Presentation & panel: What’s the latest thinking and research on breaking the barriers
to solid tumours by:
Targeting galectin-9 for immune restoration in solid tumors : rationale and problems to
be solved
harnessing new understanding of the tumour microenvironment?
utilising combinations (eg. with checkpoint inhibitors)?
making T cells intrinsically more effective and more resistant?
Dr Pierre Busson, Group Leader, Tumor Microenvironment, Exosomes & microRNAs in
Solid Tumors, Gustave Roussy
Dr Andrea Van Elsas, Chief Scientific Officer, Aduro Biotech Europe
5.45 Close of Phacilitate Immunotherapy Europe 2016